Intergroup Exemestane Study mature analysis: overall survival data

Anticancer Drugs. 2008 Feb;19 Suppl 1:S3-7. doi: 10.1097/01.cad.0000277608.23376.bc.

Abstract

The findings of the Intergroup Exemestane Study (IES) challenge the standard adjuvant endocrine therapy consisting of 5 years of tamoxifen therapy in women with oestrogen receptor-positive breast cancer. The IES study confirmed that switching to an aromatase inhibitor (AI) such as exemestane after 2-3 years of tamoxifen therapy resulted in improved survival relative to women remaining on 5 years of tamoxifen therapy. Data from IES concur with the findings of other studies with AIs that support the rationale of switching from tamoxifen to an AI after 2-3 years of tamoxifen in postmenopausal women who remain disease-free.

Publication types

  • Comparative Study

MeSH terms

  • Androstadienes / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Aromatase Inhibitors / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / mortality
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Neoplasms, Hormone-Dependent / metabolism
  • Neoplasms, Hormone-Dependent / mortality
  • Postmenopause
  • Receptors, Estrogen / metabolism
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Survival Rate
  • Tamoxifen / therapeutic use

Substances

  • Androstadienes
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Receptors, Estrogen
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • exemestane